Gibson Dunn & Crutcher LLP is serving as legal counsel to Neurogene Inc. and Fenwick & West LLP is serving as legal counsel to Neoleukin Therapeutics,...
Neurogene’s Merger with Neoleukin
Mirum Pharmaceuticals’ $445 Million Acquisition of Travere’s Bile Acid Product Portfolio
Gibson, Dunn & Crutcher LLP is advising Mirum Pharmaceuticals, Cooley LLP is advising Travere Therapeutics, Inc. in the transaction. Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) and Travere...
Apogee Therapeutics’ Initial Public Offering
Gibson, Dunn & Crutcher LLP is advising Apogee Therapeutics, Inc. in the offering. Apogee Therapeutics, Inc. (Nasdaq: APGE) announced the pricing of its upsized initial public offering...
Aeglea’s Acquisition of Spyre
Gibson, Dunn & Crutcher LLP is advising Spyre Therapeutics, Inc. in the transaction, while Cooley LLPis advising Aeglea. Aeglea BioTherapeutics, Inc. (“Aeglea”) (NASDAQ: AGLE), announced it has completed...
Magenta Therapeutics’ Merger with Dianthus Therapeutics
Gibson, Dunn & Crutcher LLP acted for Dianthus Therapeutics, Inc. on its merger with Magenta Therapeutics, Inc., assisted by Goodwin Procter. Magenta Therapeutics, Inc. (Nasdaq: MGTA) and Dianthus Therapeutics,...
Assertio Holdings, Inc.’s Acquisition of Spectrum Pharmaceuticals, Inc.
Guggenheim Securities, LLC is acting as financial advisor to Spectrum, and Gibson, Dunn & Crutcher LLP is serving as legal counsel. SVB Securities and H.C. Wainwright...